Neurescue Revenue and Competitors
Estimated Revenue & Valuation
- Neurescue's estimated annual revenue is currently $4.5M per year.
- Neurescue's estimated revenue per employee is $251,000
Employee Data
- Neurescue has 18 Employees.
- Neurescue grew their employee count by -10% last year.
Neurescue's People
Name | Title | Email/Phone |
---|---|---|
1 | Founder & CEO | Reveal Email/Phone |
2 | Senior Clinical & Scientific Affairs Director | Reveal Email/Phone |
Neurescue Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $6.1M | 49 | -18% | $10M | N/A |
#2 | $30.4M | 121 | 29% | N/A | N/A |
#3 | $139.8M | 913 | -3% | $200K | N/A |
#4 | $84.1M | 0 | N/A | $1.2M | N/A |
#5 | $43.4M | 173 | 30% | N/A | N/A |
#6 | $64.5M | 257 | 12% | N/A | N/A |
#7 | $64.3M | 205 | 26% | $129.6M | N/A |
#8 | $19.6M | 78 | -7% | N/A | N/A |
#9 | $65.8M | 262 | 7% | N/A | N/A |
#10 | $73.7M | 235 | 20% | $115.5M | N/A |
What Is Neurescue?
Neurescue, a medical device manufacturer based in Denmark, is developing cardiovascular devices to help emergency patients. Our first product, the NEURESCUE device, is the first computer-aided aortic occlusion catheter. This procedure redirects blood flow to the central circulation. Our future goal is to enable the clinical utility of further intelligent procedures.
keywords:N/AN/A
Total Funding
18
Number of Employees
$4.5M
Revenue (est)
-10%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Neurescue News
2022-04-13 - Balloon Catheters Market Contemplated to Witness a Tremendous CAGR of 8.78%
by 2026, As per DelveInsight
In June 2021, Neurescue received the 510k clearance from the US Food and Drug Administration for their NEURESCUE® device, 'the world's first...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $1.6M | 18 | 0% | N/A |
#2 | $2.5M | 18 | 6% | N/A |
#3 | $1.6M | 18 | 20% | N/A |
#4 | $3.6M | 18 | 38% | $22M |
#5 | $4.5M | 18 | 38% | N/A |